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Several hormones are regulated by circadian rhythms to adjust the metabolism to the 2 
light/dark cycles and feeding/activity patterns throughout the day. Circadian rhythms 3 
are mainly governed by the central clock located in the suprachiasmatic nucleus but also 4 
by clocks present in peripheral organs, like the endocrine pancreas. Plasma glucose 5 
levels and the main pancreatic hormones insulin and glucagon also exhibit daily 6 
variations. Alterations in circadian rhythms are associated with metabolic disturbances 7 
and pathologies like obesity and diabetes. The molecular components of central and 8 
peripheral clocks and their regulatory mechanisms are well established. Among the 9 
different clock genes, Rev-erb alpha is considered one of the key links between 10 
circadian rhythms and metabolism. Rev-erb alpha is a critical part of a negative 11 
feedback loop in the core circadian clock and modulates the clock oscillatory properties. 12 
Additionally, Rev-erb alpha plays an important role in the regulation of lipid and 13 
glucose metabolism, thermogenesis, adipocyte and muscle differentiation as well as 14 
mitochondrial function. In the endocrine pancreas, Rev-erb alpha regulates insulin and 15 
glucagon secretion and pancreatic β-cell proliferation. In the present review, we discuss 16 
all these subjects and, particularly, the role of the clock gene Rev-erb alpha in the 17 
endocrine pancreas. 18 
 19 
 20 
Key Words: Rev-erb alpha, clock genes, glucose homeostasis, type 2 diabetes, insulin 21 





Glucose homeostasis is mainly regulated by the two main endocrine cell 26 
populations of the pancreas. Pancreatic α and β-cells are the most abundant cell types of 27 
the islet of Langerhans, and their opposite and complementary secretory activity is 28 
necessary for an adequate control of plasma glucose levels within a physiological range. 29 
Elevation of glucose concentrations stimulates insulin release from pancreatic β-cells, 30 
while hypoglycaemic conditions activate glucagon secretion from α-cells [1,2]. Among 31 
other metabolic functions, insulin promotes glucose uptake by the skeletal muscle and 32 
the adipose tissue, while inhibits hepatic glucose production. These processes lead to 33 
hypoglycaemic effects, decreasing plasma glucose concentrations. On the contrary, 34 
glucagon acts mainly on the liver, inducing glycogenolysis and gluconeogenesis and, 35 
subsequently, activating hepatic glucose output [1,2]. These processes lead to the rise of 36 
plasma glucose levels. In this manner, plasma glucose is regulated by the opposite role 37 
of insulin and glucagon and the complementary function of pancreatic α and β-cells at 38 
low and high glucose concentrations.  39 
The abnormal function of the endocrine pancreas can result in impaired glucose 40 
tolerance and eventually, in type 2 diabetes. Metabolic conditions like obesity are 41 
associated with insulin resistance, which involves an attenuated action of this hormone 42 
on peripheral tissues. In response to this resistance, several morphological and 43 
functional adaptations allow the endocrine pancreas to secrete higher insulin levels to 44 
satisfy the increased demand imposed by insulin resistance in order to maintain normal 45 
plasma glucose levels [3,4]. When insulin resistance is not adequately compensated by 46 
an efficient pancreas adaptation, glucose tolerance becomes impaired. This situation can 47 
progress to overt hyperglycaemia and type 2 diabetes when β-cell function and/or 48 
viability become highly deteriorated. In addition to the pancreatic β-cell, alterations in 49 
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the pancreatic α-cell mass and glucagon secretion are also involved in the 50 
pathophysiology of diabetes [1,2]. It has been reported that increased plasma glucagon 51 
levels (in absolute terms or relative to those of insulin) can increase hepatic glucose 52 
output, exacerbating the hyperglycaemia in diabetes. Increased α-cell mass (relative to 53 
β-cells) and lack of suppression of glucagon secretion by hyperglycaemia may also 54 
contribute to excessive glucagon signalling [1,2]. Thus, both α and β-cells play a key 55 
role not only in glucose homeostasis but also in diabetes.  56 
 Circadian rhythms are important to adapt the metabolism to the changing 57 
conditions of the day/night and rest/activity daily cycles. In this regard, the pancreas 58 
function and the regulation of glucose homeostasis are also subjected to circadian 59 
control mechanisms [5]. Several features of the lifestyle of modern societies like shift 60 
working, jet lag, impaired sleeping or artificial light can negatively affect the optimal 61 
function of circadian rhythms. A growing body of evidence indicates that these 62 
alterations in the circadian regulation may be also associated to metabolic pathologies 63 
like obesity and type 2 diabetes [5]. In recent years, the molecular nature of the different 64 
circadian clocks located in the brain and in peripheral tissues has been revealed. At the 65 
molecular level, the main components of the core clock machinery are CLOCK and 66 
BMAL1, which regulate both the transcription of different genes involved in 67 
metabolism and the expression of other clock genes involved in two regulatory 68 
feedback loops of the molecular clock (Figure 1). In one of these loops, PER and CRY 69 
proteins repress CLOCK and BMAL1 expression, while in the other feedback 70 
mechanism, the nuclear receptors REV-ERB ALPHA and ROR ALPHA repress or 71 
activate Bmal1, respectively. Among the different genes involved in the control of the 72 
circadian system, we will discuss here the function of the clock gene Rev-erb alpha in 73 
metabolism and the pancreatic function. 74 
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Clock genes in glucose homeostasis and type 2 diabetes. 76 
The plasma levels of glucose and several hormones involved in glucose 77 
homeostasis such as insulin and glucagon display circadian variations. Insulin peaks 78 
during the day to increase energy storage and utilization in humans [6-8]. In contrast, 79 
insulin secretion decreases and glucagon increases during night time to increase hepatic 80 
glucose production and maintain plasma glucose levels within a physiological range [8]. 81 
Thus, daily plasma oscillations in pancreatic hormones can be also regulated 82 
independent of fasting/feeding behaviour in animals and humans [7]. These daily cycles 83 
suggest an important role of the circadian regulation of glucose homeostasis, which 84 
involves the control by the suprachiasmatic nucleus (SCN) in addition to the 85 
sympathovagal balance of the autonomic system. 86 
Alteration of circadian rhythms has been associated with obesity and diabetes 87 
[9]. Circadian disruption can occur by impaired function of the molecular circuitry in 88 
the different internal clocks and also by desynchronization between the SCN and the 89 
external environmental cues or the peripheral clocks. In modern societies, the natural 90 
circadian rhythms can be impaired by the current lifestyle: high-fat diet (HFD) and 91 
excessive calories, jetlag, shift work, sleep loss and exposure to light at night are among 92 
several factors that are considered to alter circadian rhythms, which may further 93 
contribute to the increasing epidemics in obesity and diabetes. For instance, shift 94 
workers have increased risk of developing cardiovascular disease, metabolic syndrome, 95 
cancer, obesity and type 2 diabetes [10-15] and alterations in the pancreatic β-cell 96 
responses, glucose and lipid metabolism [13,16,17]. Poor sleep or reducing sleeping 97 
time leads to increased body mass index, elevated ghrelin, reduced leptin levels and 98 
insulin resistance [18-20]. Moreover, first-degree relatives of patients with type 2 99 
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diabetes had shorter insulin secretion circadian cycles that lack real periodicity 100 
compared to healthy subjects [21].  101 
Several animal models with genetic modifications in clock genes have revealed 102 
their key regulatory function in metabolism and glucose homeostasis. For instance, 103 
Clock mutant mice exhibited attenuated diurnal feeding rhythm, hyperphagia and 104 
obesity [22]. In addition, they developed a metabolic syndrome characterized by 105 
hyperleptinemia, hyperlipidemia, hepatic steatosis, hyperglycaemia, and 106 
hypoinsulinaemia. Mice deficient in Bmal1 showed altered adipogenesis and hepatic 107 
carbohydrate metabolism [23,24]. Later studies showed that Clock mutant mice as well 108 
as global and pancreas-specific Bmal1 knockout (KO) mice had clear diabetic features 109 
such as hyperglycaemia and hypoinsulinaemia [25]. Genetic manipulation of other 110 
clock genes has also demonstrated the importance of these genes in metabolism and 111 
energy homeostasis. Per2 KO mice had altered lipid metabolism with reduced total 112 
triacylglycerol and nonesterified fatty acids [26]. Double Cry1 and Cry2 KO mice 113 
exhibited glucose intolerance and alterations in glucose and lipid metabolism [27]. Cry1 114 
overexpression in the liver down-regulated gluconeogenesis during fasting [28]. 115 
Additionally, this overexpression resulted in increased insulin sensitivity and lower 116 
glycaemic levels in diabetic animals [28]. Mice lacking the nuclear receptors REV-ERB 117 
ALPHA and ROR ALPHA decreased adiposity and HDL levels [29-31]. Altered lipid 118 
metabolism was also found in the double KO mice for Rev-erb alpha and beta [32]. 119 
Therefore, alterations in clock genes can lead to disturbances in energy and metabolism, 120 
which may promote metabolic diseases like obesity and type 2 diabetes. 121 
 122 
Rev-erb alpha and its function in metabolism 123 
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The nuclear receptor REV-ERB ALPHA (also known as NR1D1) was first 124 
mapped to the reverse strand of the gene thyroid hormone receptor alpha and considered 125 
an orphan receptor. The endogenous ligand of REV-ERB ALPHA was later discovered 126 
to be the metabolite heme [33,34], which is an important molecule for cellular redox 127 
balance and mitochondrial function [35]. In addition to sensing the metabolic state of 128 
the cell, REV-ERB ALPHA has been proposed to link circadian rhythms to metabolism 129 
in several tissues [36]. In mice, Rev-erb alpha gene expression was found to exhibit 130 
circadian oscillations in different tissues including skeletal muscle, kidney and thymus 131 
[37,38], and the lack of this nuclear receptor shortened the period of behavioural 132 
rhythms, suggesting an important role in stabilizing circadian oscillations [31]. Mice 133 
lacking REV-ERB ALPHA showed impaired regulation of cholesterol, bile acid 134 
metabolism [30,39] and apolipoprotein CIII [40]. More recent studies using genomic 135 
techniques demonstrated that REV-ERB ALPHA bound genes were involved in lipid 136 
metabolism [41]. Besides regulating lipid metabolism, REV-ERB ALPHA was shown 137 
to regulate glucose de novo synthesis by heme-induced REV-ERB ALPHA activation 138 
and repression of the gluconeogenic Pepck gene in human hepatoma cells [34]. Studies 139 
in brown adipose tissue from mice lacking REV-ERB ALPHA demonstrated an 140 
important role of this nuclear receptor in body temperature by regulating Ucp1 gene 141 
expression [42]. Additionally, mouse adipocytes cell lines showed a requirement of 142 
Rev-erb alpha in adipocyte differentiation and its interaction with PPARgamma [43]. In 143 
humans, different Rev-erb alpha polymorphisms were associated with obesity in 144 
heterogeneous populations [44-46]. Interestingly, Rev-erb alpha expression was 145 
upregulated in visceral adipose tissue from obese women as compared to lean 146 
individuals over the course of 24 h and this increased expression was associated with 147 
metabolic syndrome [47]. In subcutaneous adipose tissue from young obese subjects, a 148 
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positive correlation was found between Rev-erb alpha and the body mass index, 149 
highlighting the importance of this nuclear receptor in obesity and metabolic syndrome. 150 
Similar to liver and adipose tissue, Rev-erb alpha mRNA levels also oscillate in a 151 
circadian manner in mouse skeletal muscle [38]. Studies in C2C12 cells demonstrated 152 
that REV-ERB ALPHA is a repressor of genes involved in muscle differentiation [48]. 153 
Recently, it was shown that REV-ERB ALPHA can affect mitochondrial content and 154 
function by modulating the AMPK (AMP activated protein kinase) pathway in skeletal 155 
muscle [49]. REV-ERB ALPHA deficiency resulted in inhibition of the liver kinase b 156 
1(LKB-1)-AMPK-NAD-dependent deacetylase sirtuin-1 (SIRT-1)–Peroxisome 157 
proliferator-activated receptor gamma coactivator 1 alpha (PPARGC-1 alpha) signalling 158 
pathways in skeletal muscle. Indeed, a previous study with mice treated in vivo with the 159 
AMPK activator AICAR suggested a link between the AMPK pathway and clock genes 160 
including Rev-erb alpha in mouse skeletal muscle [50]. The mechanism suggested was 161 
via AMPK gamma3 subunit, which was previously shown to control mitochondrial 162 
biogenesis [51].  163 
 164 
Rev-erb alpha and its function in the molecular clock.  165 
 The central clock located in the SCN and the clocks located in peripheral organs 166 
have a common molecular structure consisting of transcriptional/post translational feed 167 
back loops that generate circadian rhythms. The core clock machinery composed of 168 
CLOCK and BMAL1 activates the transcription of other clock genes including Per and 169 
Cry (Figure 1). PER and CRY proteins repress CLOCK/BMAL1, inhibiting their own 170 
transcription, and allowing new cycles to start, which govern the circadian oscillatory 171 
pattern. The nuclear receptors REV-ERB ALPHA and ROR ALPHA are part of the 172 
additional feedback loop repressing or activating Bmal1, respectively. REV-ERB 173 
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ALPHA and REV-ERB BETA, a high similar transcription factor, were shown to play 174 
a crucial role in circadian rhythm generation [52]. Loss of REV-ERB ALPHA and 175 
REV-ERB BETA abrogated circadian gene expression in mouse embryonic fibroblasts 176 
[52]. Furthermore, genetic deletion of both Rev-erb alpha and beta in adult mice led to 177 
the loss of rhythmicity in the wheel running behaviour, demonstrating the importance 178 
of these two transcription factors as components of the clock machinery [32]. In both 179 
hypothalamic and peripheral clocks, Rev-erb alpha oscillates in a circadian manner. In 180 
the brain, Rev-erb alpha is expressed in the supraquiasmatic nucleus [31], hippocampus 181 
[53] and mid brain [54]. In the latter two areas, Rev-erb alpha repressed hydroxylase, 182 
the rate-limiting enzyme in dopamine biosynthesis [53,54]. In Rev-erb alpha null mice, 183 
the abnormalities of hippocampus functions caused impaired memory and novelty-184 
induced hyperactivity [53], whereas abnormalities in mid brain led to aggression, 185 
anxiety and depression-like behaviours [54]. Pharmacological interventions using REV-186 
ERB ALPHA and BETA synthetic ligands were shown to modulate circadian both 187 
behaviour and metabolism [55-59]. Administration of synthetic REV-ERB ligands in 188 
mice disrupted the circadian pattern of clock genes in the hypothalamus and altered the 189 
circadian behaviour, while improved dyslipidemia and hyperglycaemia in high fat diet 190 
treated mice [58]. In addition, synthetic REV-ERB ALPHA agonists increased 191 
mitochondrial content and exercise capacity in skeletal muscle [49].  192 
 193 
Role of Rev-erb alpha in the pancreatic β-cell and insulin secretion. 194 
The clock gene Rev-erb alpha is expressed in the rat pancreas [60], mouse 195 
pancreas [61] as well as mouse and human islets [25,61-63]. Its expression has been 196 
also reported in the insulin-releasing cell lines MIN6 [63] and INS-1 [64], which are 197 
derived from mouse and rat, respectively. Additionally, Rev-erb alpha expression was 198 
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found to follow a circadian pattern in the majority of these cell models. The role of Rev-199 
erb alpha has been examined in MIN6 cells and in pancreatic islets using small 200 
interfering RNA (siRNA) [63]. When both isolated mouse islet cells and MIN6 cells 201 
were treated with a siRNA to down-regulate Rev-erb alpha, the expression of the 202 
lipogenic genes sterol regulatory element binding protein 1c (Srebp-1c) and fatty acid 203 
synthase (Fas) were decreased. Rev-erb alpha has been reported to have a key role in 204 
the regulation of lipid metabolism in the adipose tissue and the liver [29,32]. However, 205 
in contrast to the effects on mouse islets and MIN6 cells, REV-ERB ALPHA synthetic 206 
agonists inhibited the lipogenic genes Srebp-1c and Fas in liver and in insulinoma-207 
derived INS-1 cells [58,64]. Thus, these effects might be species and tissue-specific. In 208 
MIN6 cells, down-regulation of Rev-erb alpha did not affect apoptosis but decreased 209 
proliferation, effect that was also observed in primary mouse pancreatic β-cells [63] 210 
(Figure 2). This is in line with findings obtained in isolated islets from Clock mutant 211 
mouse: the expression of different genes involved in islet growth and development like 212 
CyclinD1, Pdx1 or Hnf4α was found decreased [25]. Given that Rev-erb alpha 213 
expression was also altered in these Clock mutant mice, it is plausible that the effect on 214 
proliferation found in MIN6 and primary β-cells was also related with changes in these 215 
genes regulating islet growth and development. 216 
Furthermore, down-regulation of Rev-erb alpha in both MIN6 cells and isolated 217 
mouse islet cells led to impaired glucose-stimulated insulin secretion (GSIS) after 24 h 218 
of treatment with siRNA [63] (Figure 2). This effect was not associated to changes in 219 
insulin expression or insulin protein content. However, several genes like Vamp3, 220 
Munc18, Snap25 and Syntaxyn1A, whose proteins are essential in exocytosis, exhibited 221 
a reduced expression. This down-regulated expression of exocytotic proteins has been 222 
also observed in pancreatic islets from Clock mutant mice [25], further indicating that 223 
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the clock machinery may have an important role in the later stages of GSIS. Rev-erb 224 
alpha expression was found to exhibit a circadian pattern in isolated islets from lean 225 
mice treated with a normal diet. However, HFD feeding to induce obesity was able to 226 
change the circadian expression found in isolated islets from lean mice [63]. These 227 
altered patterns after HFD feeding were also found in other clock genes like Clock, 228 
Bmal1 and Per1. Similar HFD effects have been reported in other tissues like 229 
hypothalamus, adipose tissue and liver [65]. Interestingly, GSIS from islets of both lean 230 
and obese mice followed a similar circadian pattern as the one followed by Rev-erb 231 
alpha expression, further suggesting that the function of this clock gene may affect 232 
insulin secretion [63]. 233 
In addition to this long-term genomic effects, treatment of MIN6 cells with 234 
hemin, a natural ligand of REV-ERB ALPHA [33], as well as synthetic modulators of 235 
this clock gene, led to rapid GSIS changes [63]. In insulin-secreting INS-1 cells, the 236 
application of a REV-ERB ALPHA agonist also led to increased insulin release [64]. In 237 
agreement with the long-term effects mentioned earlier, these findings further supported 238 
the idea that Rev-erb alpha contributes to GSIS. Given that these effects with the REV-239 
ERB ALPHA modulators were produced after 1 h of incubation with the different 240 
agents, it is very likely that altered GSIS in these conditions was the result of non-241 
genomic rapid actions. In any case, whether these effects were directly mediated by 242 
REV-ERB ALPHA or by other mechanisms need to be elucidated. Indeed, several 243 
pleiotropic effects have been attributed to clock genes different to those regulating 244 
circadian systems, particularly in the case of Rev-erb alpha [5]. Additionally, hemin has 245 
been reported to block large conductance K+ channels in neurons of the rat brain [66], 246 
which could affect electrical activity, calcium signals and insulin secretion in the 247 
pancreatic β-cell. Moreover, it has been suggested that hemin may rapidly affect the 248 
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activation of the MAPK (mitogen activated protein kinase) pathway in neurons of the 249 
SCN [67]. 250 
The regulation of Rev-erb alpha expression by extracellular messengers has 251 
been also studied in the pancreatic β-cell. In vivo treatment of mice with leptin for 5 252 
days led to increased Rev-erb alpha mRNA levels in the pancreatic islets [63]. In vitro 253 
leptin application produced a similar effect in islets from wild-type and leptin-deficient 254 
ob/ob mice, but did not modify Rev-erb alpha expression in islets from db/db mice, 255 
which lack leptin receptors. This finding was also observed in insulin-producing MIN6 256 
cells. While blockade of the JAK/STAT (janus kinase/signal transducer and activator of 257 
transcription) and the PI3K (phosphatidylinositide 3-kinase) pathways did not affect 258 
leptin actions, inhibition of the MAPK cascade completely abrogated leptin-induced 259 
Rev-erb alpha expression in isolated mouse islets [63]. It has been also reported in rat 260 
insulinoma-derived INS-1 cells that activation of melatonin receptors decreased the 261 
activity of the cAMP/protein kinase A/CREB (cAMP response element-binding protein) 262 
pathway, leading to augmented Rev-erb alpha expression and activity, while forskolin 263 
application induced the opposite effects [64].  264 
 265 
Role of Rev-erb alpha in the pancreatic α-cell and glucagon secretion. 266 
As mentioned earlier, pancreatic α-cells play a key role in glucose homeostasis 267 
and in the pathophysiology of diabetes [2]. Pancreatic α-cells augment their secretory 268 
activity at low glycaemic concentrations, increasing plasma glucagon levels, which 269 
activate hepatic glucose output. In diabetes, a relative or absolute hyperglucagonemia 270 
may aggravate the hyperglycaemia of these patients. Although glucagon secretion 271 
follows an oscillatory daily pattern [68], little is known about the presence of molecular 272 
oscillators in the pancreatic α-cell. The mouse-derived α-cell line αTC1-9 expresses 273 
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Clock, Bmal1, Per1, Per2, Cry1, Cry2 and Rev-erb alpha. It was reported that the 274 
expression of this latter clock gene oscillated along the day at low glucose 275 
concentrations. However, elevation of glucose levels to 11 mM inhibited this oscillatory 276 
behaviour in αTC1-9 cells and decreased Rev-erb alpha mRNA levels in mouse 277 
pancreatic α-cell preparations enriched by fluorescence activated cell sorting [69]. 278 
Incubation of αTC1-9 cells with Rev-erb alpha siRNA for 24 h impaired glucagon 279 
secretion induced by low glucose levels (0.5 mM) (Figure 3). No effect was observed at 280 
11 mM glucose, condition at which glucagon secretion is already highly inhibited [2]. 281 
After the siRNA treatment, several genes coding for exocytotic proteins like Munc18 282 
and Syntaxin1A were found decreased (Figure 3). This is in agreement with studies in 283 
pancreatic islets treated with Rev-erb alpha siRNA [63] and islets isolated from Clock 284 
mutant mice [25]. Although all these findings indicate that REV-ERB ALPHA may 285 
play an important function in exocytosis and glucagon secretion, further examination in 286 
primary pancreatic α-cells is still required. Another important aspect is the glucose 287 
regulation of Rev-erb alpha expression in pancreatic α-cells. A similar glucose 288 
modulation has been reported with Per1, Per2, Dbp and Rev-erb alpha in fibroblasts 289 
[70,71]. 290 
AMPK plays a key role in glucose-modulated glucagon secretion [72]. Its 291 
activation has been related with glucagon release from pancreatic α-cells at low glucose 292 
concentrations. Additionally, this protein has been implicated in the regulation of 293 
peripheral clocks located in liver, adipose tissue and skeletal muscle among others 294 
[50,71]. AMPK activation enables the clock gene Cry to transduce nutrient signals like 295 
glucose to circadian clocks, affecting Rev-erb alpha among other clock genes [71]. In 296 
αTC1-9 cells, AMPK activation by metformin prevented the inhibitory effect of high 297 
glucose levels on Rev-erb alpha expression [69], suggesting that AMPK also has an 298 
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important role in the pancreatic clock function. It has been shown that metabolic 299 
sensing by the clock machinery may depend on changes in the cellular redox state, 300 
involving nicotinamide phosphoribosyltransferase (NAMPT) and NAD-dependent 301 
deacetylase sirtuin-1 (SIRT1) [73-76]. CLOCK:BMAL1 regulate NAMPT transcription 302 
in a circadian manner, which is probably responsible for the oscillatory behaviour in 303 
NAD+ levels. NAD+-sensitive SIRT1 also displays circadian changes and has been 304 
found to affect CLOCK:BMAL1 activity by deacetylation of both BMAL1 and PER2 305 
[73,74]. In αTC1-9 cells, Nampt and Sirt1 expression decreased in the presence of high 306 
glucose levels, effect that was prevented by metformin treatment [69]. Incubation of 307 
αTC1-9 cells with a NAMPT inhibitor, led to a decrease in Sirt1 and Rev-erb alpha 308 
expression at low glucose concentrations, which was also accompanied by reduced 309 
glucagon release. All these findings indicate that glucose can regulate glucagon 310 
secretion via an AMPK/NAMPT/SIRT1 pathway that involves the participation of 311 
REV-ERB ALPHA [69] (Figure 3). Similarly, this pathway and its modulation by 312 
glucose restriction has been also reported in skeletal muscle [77,78]. Furthermore, 313 
AMPK activation by metformin rescued the altered expression in several clock genes in 314 
the white adipose tissue of obese mice [77]. These effects were mediated by the 315 
AMPK/NAMPT/SIRT1 pathway, which is in line with the findings in αTC1-9 cells 316 
[69]. Although the modulation of molecular clocks and circadian rhythms by AMPK 317 
has been reported in several tissues [69,71,77], studies in heart, fat tissue and muscle 318 
from AMPK knock out mice indicate that this AMPK modulation may be tissue-319 
specific [79]. 320 
Similarly to the situation discussed earlier for the β-cells [63], treatment of 321 
αTC1-9 cells with synthetic modulators of REV-ERB ALPHA or its natural ligand 322 
hemin showed rapid effects, which were unlikely to be genomic [69]. Hemin incubation 323 
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for 90 min increased glucagon release at both low and high glucose levels. In contrast, 324 
GSK4112, a REV-ERB ALPHA agonist [55], which was incubated for 60 min, only 325 
augmented glucagon release from αTC1-9 cells at low glucose concentrations. 326 
Glucagon secretion in pancreatic α-cells is largely controlled by Ca2+ signalling [2]. The 327 
agonist effect on glucagon secretion seemed to be mediated by Ca2+ signals, since its 328 
application rapidly increased the intracellular Ca2+ concentrations at low glucose levels 329 
[69]. The REV-ERB ALPHA antagonist SR8278 [80] produced the opposite effect on 330 
glucagon release and Ca2+ signalling in αTC1-9 cells. As we have commented earlier 331 
for the pancreatic β-cell, further studies are required to know whether these rapid effects 332 
were directly mediated by REV-ERB ALPHA or by other pathways. It would be 333 
interesting to analyze if these REV-ERB ALPHA modulators can regulate the activity 334 
of Ca2+ channels, as has been described for hemin in the case of neuron BK channels 335 
[66]. 336 
 337 
Conclusions and future perspectives. 338 
 REV-ERB ALPHA seems to form a robust link between circadian rhythms, 339 
internal clocks and metabolism. REV-ERB ALPHA plays a key function in the 340 
regulation of the clock machinery, since its transcription depends on CLOCK/BMAL1 341 
activity and, at the same time, REV-ERB ALPHA proteins inhibit Bmal1 expression, 342 
establishing a negative feedback loop. Moreover, Rev-erb alpha has been involved in 343 
lipid and glucose metabolism, thermogenesis, adipocyte and muscle differentiation as 344 
well as mitochondrial biogenesis. In humans, several Rev-erb alpha polymorphisms 345 
have been associated with obesity and metabolic syndrome. In the endocrine pancreas, 346 
the clock gene Rev-erb alpha exhibits a circadian pattern and regulates insulin and 347 
glucagon secretion, probably by modulating the expression of exocytotic proteins. A 348 
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metabolic challenge like HFD feeding in mice alters the normal expression of Rev-erb 349 
alpha in the pancreatic islets as well as their circadian insulin release. Additionally, it 350 
has been shown that this clock gene is involved in pancreatic β-cell proliferation. Thus, 351 
REV-ERB ALPHA plays a key role in several processes related with the physiology of 352 
pancreatic α and β-cells. Given that little information is still available about Rev-erb 353 
alpha regulation in the endocrine pancreas, much work is required to unravel the 354 
molecular mechanisms involved in the control and actions of this clock gene in α and 355 
β-cells.  356 
 Since REV-ERB ALPHA seems to be important in insulin secretion at high 357 
glucose concentrations and in glucagon release at low glucose levels, the specific 358 
modulation of this clock gene in both cell types may be of therapeutic interest in 359 
diabetes, obesity and metabolic syndrome. In this regard, it has been reported that 360 
treatment of diet-induced obese mice with synthetic REV-ERB agonists improved 361 
glycaemia and plasma lipids as well as decreased fat mass and body weight in these 362 
animals [58]. Additionally, activation of REV-ERB ALPHA by synthetic agonists 363 
increased muscle oxidative metabolism and exercise capacity by improving 364 
mitochondrial function [49]. Although these agonists seem to be useful to promote 365 
health benefits in metabolic disorders, a better understanding of the multiple REV-ERB 366 
effects on circadian physiology and metabolism in central and peripheral organs is 367 
required. This will be necessary to design specific strategies targeted to the different 368 
pathologies and tissues, like the endocrine pancreas, and to minimize non-desired 369 
actions and side effects. 370 
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FIGURE LEGENDS 380 
Figure 1. Molecular components of the core circadian clock. The positive arm, 381 
BMAL1 and CLOCK, drives the transcriptional expression of the negative arm, PERs 382 
and CRYs. PER and CRY proteins form a complex that inhibits their own 383 
CLOCK:BMAL1-induced transcription. The positive arm (CLOCK and BMAL1) also 384 
drives the transcriptional expression of CCGs, REV-ERBs and RORs. The later two 385 
inhibit and activate BMAL1 expression, respectively. BMAL1, brain and muscle 386 
ARNT-like 1; CLOCK, circadian locomotor output cycles protein kaput; PER, period 387 
homolog drosophila; CRY, cryptochrome; CCGs, clock controlled genes; REV-ERB, 388 
reverse-eritroblastosis virus; RORs, retinoic acid receptor-related orphan receptor; 389 
RORE, ROR response element.  390 
 391 
Figure 2. Role of REV-ERB ALPHA in the regulation of pancreatic β-cell function. 392 
When plasma glucose concentrations rise, this sugar enters the cell through the glucose 393 
transporter 2 (GLUT-2) and is metabolized via glycolysis and the Krebs cycle. This 394 
results in the rapid increase of the ATP/ADP ratio, which induces the closure of ATP-395 
sensitive K+ channels (KATP). The blockade of these channels leads to plasma 396 
membrane depolarization, activating voltage-gated Ca2+ channels. The subsequent Ca2+ 397 
influx triggers insulin release through exocytosis of insulin secretory granules. REV-398 
ERB ALPHA also regulates insulin secretion probably via modulation of the exocytotic 399 
process and the proteins involved. REV-ERB ALPHA also regulates β-cell proliferation 400 
and genes involved in lipid metabolism. 401 
 402 
Figure 3. Role of REV-ERB ALPHA in the regulation of pancreatic α-cell 403 
function. Glucose is transported into the α-cells through the glucose transporter 1 404 
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(GLUT-1). According to the most cited model for the α-cell stimulus-secretion coupling 405 
[81], at low glucose concentrations the ATP/ADP level is sufficient to partially close 406 
the ATP-sensitive K+ channels (KATP). This results in a small depolarization that 407 
generates an intermediate membrane potential at which voltage-gated Na+ and Ca2+ 408 
channels are activated. The increase in the cytoplasmic Ca2+ concentration stimulates 409 
glucagon secretion. Additionally, the low ATP concentrations would activate the 410 
AMPK-NAMPT-SIRT1 pathway, which turns on the CLOCK/BMAL1 complex and, 411 
consequently, increases REV-ERB ALPHA expression. REV-ERB ALPHA probably 412 
regulates glucagon secretion via modulation of the exocytotic process. BMAL1, brain 413 
and muscle ARNT-like 1; CLOCK, circadian locomotor output cycles protein kaput; 414 
REV-ERB, reverse-eritroblastosis virus; AMPK, AMP activated protein kinase; 415 
NAMPT, nicotinamide phosphoribosyltransferase; SIRT-1, NAD-dependent 416 
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